Recro Appoints Eduardo Uribe as Head of Quality for Recro San Diego
19 Enero 2022 - 6:00AM
Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development
and manufacturing organization (CDMO) dedicated to solving complex
formulation and manufacturing challenges primarily in small
molecule therapeutic development, today announced the appointment
of Eduardo Uribe as the company’s head of quality for Recro San
Diego. Mr. Uribe has more than 30 years of experience developing,
implementing and managing quality systems within the biotechnology
and pharmaceutical industry, including more than a decade in senior
leadership positions overseeing quality and compliance at a number
of leading CDMOs. In his new role with Recro, he will be
responsible for strategic planning and management of all quality
and compliance initiatives for the company’s San Diego
operations.
“We continue to make excellent progress
integrating our San Diego operations and building out a top-tier
leadership team to oversee our West Coast activities, highlighted
most recently by Eduardo’s appointment as head of quality. These
operational advances and team expansions are all taking place
concurrent with our ongoing leveraging of our San Diego-based
capabilities and expertise to grow our business through new
customer wins and the expansion of existing client relationships,”
said David Enloe, president and chief executive officer of Recro.
“Quality is one of the most critical pillars of the Recro
organization and having a leader with Eduardo’s experience and
track record of excellence will ensure that it remains a key
differentiator for the company as we continue to grow our San Diego
business. We welcome him to the Recro team and look forward to the
important contributions he will make to our success.”
Mr. Uribe most recently served as vice president
of quality and regulatory compliance at Cambrex Corporation
(previously Avista Pharma Solutions prior to its 2019 acquisition
by Cambrex Corporation). In this role, he oversaw quality systems
inclusive of lab and manufacturing quality and served as a quality
liaison to support the growth of the company’s CDMO business. In
addition, he led the successful commercialization of multiple U.S.
facilities, while also directing additional facility expansions and
integration of a consistent quality management system across all
business units. Mr. Uribe previously served as Gilead Sciences’
director of quality and site quality head for biologics at its
Oceanside, CA, facility. During his tenure with Gilead, he was
charged with CDMO oversite of drug substance and drug product for
monoclonal projects, while also supervising quality and compliance
for the company’s Oceanside operations spanning early phase to
commercial biologic products.
During his career, Mr. Uribe has also held the
position of senior director of quality services, manufacturing and
analytical labs for AAI Pharma Servies (now ALCAMI), as well as
manager of quality and quality control for EMD Millipore (now
MilliporeSigma).
About RecroRecro (NASD: REPH)
is a bi-coastal contract development and manufacturing organization
(CDMO) with capabilities spanning pre-Investigational New Drug
(IND) development to commercial manufacturing and packaging for a
wide range of therapeutic dosage forms with a primary focus in the
area of small molecules. With an expertise in solving complex
manufacturing problems, Recro is a leading CDMO providing
therapeutic development, end-to-end regulatory support, clinical
and commercial manufacturing, aseptic fill/finish, lyophilization,
packaging and logistics services to the global pharmaceutical
market.
In addition to our experience in handling DEA
controlled substances and developing and manufacturing
modified-release dosage forms, Recro has the expertise to deliver
on our clients’ pharmaceutical development and manufacturing
projects, regardless of complexity level. We do all of this in our
best-in-class facilities, which total 145,000 square feet, in
Gainesville, Georgia and San Diego, California.
For more information about Recro’s CDMO
solutions, visit recrocdmo.com.
Forward-Looking StatementsThis
press release includes forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934. These statements, among
other things, the Company’s expectations regarding the completion
of the proposed public offering, the Company’s use of proceeds from
the proposed offering, and other statements. The words
“anticipate”, “believe”, “could”, “estimate”, “upcoming”, “expect”,
“intend”, “may”, “plan”, “predict”, “project”, “will” and similar
terms and phrases may be used to identify forward-looking
statements in this press release. Our operations involve risks and
uncertainties, many of which are outside our control, and any one
of which, or a combination of which, could materially affect our
results of operations and whether the forward-looking statements
ultimately prove to be correct. Factors that could cause the
company’s actual outcomes to differ materially from those expressed
in or underlying these forward-looking statements include risks and
uncertainties associated with the ongoing economic and social
consequences of the COVID-19 pandemic, including any adverse impact
on the customer ordering patterns or inventory rebalancing or
disruption in raw materials or supply chain; demand for the
company’s services, which depends in part on customers’ research
and development and the clinical plans and market success of their
products; customers’ changing inventory requirements and
manufacturing plans; customers and prospective customers decisions
to move forward with the company’s manufacturing services; the
average profitability, or mix, of the products the company
manufactures; the company’s ability to enhance existing or
introduce new services in a timely manner; fluctuations in the
costs, availability, and suitability of the components of the
products the company manufactures, including active pharmaceutical
ingredients, excipients, purchased components and raw materials, or
the company’s customers facing increasing or new competition. These
forward-looking statements should be considered together with the
risks and uncertainties that may affect our business and future
results presented herein along with those risks and uncertainties
discussed in our filings with the Securities and Exchange
Commission at www.sec.gov. These forward-looking statements are
based on information currently available to us, and we assume no
obligation to update any forward-looking statements except as
required by applicable law.
Contacts:
Stephanie Diaz (Investors)
Vida Strategic Partners
415-675-7401
sdiaz@vidasp.com
Tim Brons (Media)
Vida Strategic Partners
415-675-7402
tbrons@vidasp.com
Ryan D. Lake (CFO)
Recro
770-531-8365
ryan.lake@recroCDMO.com
Recro Pharma (NASDAQ:REPH)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Recro Pharma (NASDAQ:REPH)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024